Share via Email

* Email To: (Separate multiple addresses with a semicolon)
* Your Name:
* Email From: (Your IP Address is
* Email Subject: (personalize your message)

Email Content:

NIH Partners with Industry to Combat COVID-19


Dr. Frances S. Collins, Director of the National Institutes of Health (NIH) has announced an initiative partnering his institute with industry leaders to accelerate progress in combating COVID-19 and future pandemics.  The Accelerating COVID-19 Therapeutic Interventions and Vaccines Initiative (ACTIV) has been established by the NIH and the Foundation for the NIH.  A total of eighteen biopharmaceutical companies, federal agencies and the EU Medicine Agency are involved.


The initiative was outlined in a viewpoint article* published in the journal of The American Medical Association.


ACTIV comprises four working groups co-shared by a scientist from NIH and a colleague from industry.


The working groups will comprise:-

  • Therapeutics Clinical Working Group to determine the benefits of drug therapy for COVID-19
  • Preclinical Working Group to evaluate testing of candidate therapy and vaccines
  • Clinical Trial Working Group to establish efficient test systems for therapy and vaccines
  • The Vaccines Working Group, focusing on evaluation of vaccine candidates

*Collins, F. S., and Stoffels, P. Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA. DOI:10.1001/jama.2020.8929 (2020)